MedTrace Logo

To Investigate the Safety, Tolerability, Pharmacokinetics and the Relative Bioavailability of BI 1026706

NCT01763333 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2019-03-25

Study results available
· View outcomes & findings →

Summary

To investigate the safety, tolerability, pharmacokinetics and the relative bioavailability of BI 1026706

Conditions

  • Healthy

Interventions

DRUG

BI 1026706 Placebo

Placebo to BI 1026706

DRUG

BI 1026706

different dose formulations

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-01-08
Primary Completion
2013-09-04
Completion
2013-09-04

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01763333 on ClinicalTrials.gov